New drug aims to outperform standard therapy in High-Risk breast cancer
NCT ID NCT06126640
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This phase 3 trial compares a new drug, SHR-A1811, to the standard treatment T-DM1 in women with HER2-positive breast cancer who still have cancer cells after initial therapy. The goal is to see if SHR-A1811 can better prevent the cancer from coming back. Participants receive either drug after surgery, and researchers track how long they remain cancer-free.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR-A1811
- What this could lead to
- If SHR-A1811 proves more effective than T-DM1, it could offer a new treatment option to reduce the risk of breast cancer returning in high-risk patients.
- What could go wrong
- This is an early-stage comparison; SHR-A1811 may not outperform T-DM1 or could have unexpected side effects. Results are not guaranteed to change standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE PRIMARY BREAST CANCER PARTICIPANTS WITH RESIDUAL INVASIVE DISEASE FOLLOWING NEOADJUVANT THERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200030, China
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, 300060, China